Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,736 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07241468RecruitingEarly Phase 1
CAR-T cell therapy for immune kidney disease
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
ShanghaiAges 18–70 - NCT05678907Recruiting
Test whether a depression questionnaire predicts relapse after discharge
This study checks whether your answers on a depression questionnaire can predict the chance of depression coming back after you leave the hospital. If it works, it may help doctors spot relapse risk earlier and plan follow-up care.
La Roche-BlancheAges 18 years+ - NCT07622277Recruiting
Teeth Alignment Stability After Braces: A Retention Study
This study compares how different face types maintain their bite after orthodontic braces are removed. Researchers will use 3D imaging to track whether teeth stay in their corrected positions during the retention phase (when you wear retainers).
Rohtak, HaryanaAges 18–45 - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT07250087RecruitingPhase 1
Asciminib maintenance after transplant or CAR T for Ph+ALL
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
Tampa, FloridaAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT07280455Recruiting
Comparing gold vs. steel retainers after braces
This study compares two types of fixed retainers (gold vs. stainless steel) to see which works better after braces are removed. It's for people aged 15–30 who have completed orthodontic treatment and have a well-aligned lower front teeth.
Baghdad, Baghdad GovernorateAges 15–30 - NCT07125794Recruiting
Brace comparison for children with relapsed clubfoot
This trial tests whether a modified version of the Denis Brawn brace works better than the original for treating relapsed clubfoot in young children who were previously treated with the Ponseti casting method.
CairoAges 2–5 - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06516679RecruitingPhase 2
Customized treatment for infants with newly diagnosed leukemia
This trial tests a treatment plan that adjusts therapy based on each baby's risk level. It aims to improve outcomes for infants newly diagnosed with certain types of leukemia.
DaeguAges Up to 2 years - NCT05599347RecruitingPhase 2
Azithromycin before anti-TNF treatment for Crohn’s disease
This Phase 2 trial tests whether taking azithromycin (an antibiotic) before starting infliximab or adalimumab can reduce the chance your body rejects the anti‑TNF medicine. It may help some people get better and keep responding to treatment.
Haifa, Haifa DistrictAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Goodyear, ArizonaAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07111273Recruiting
Predicting relapse in ulcerative colitis with early stool tests
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
Jinan, ShandongAges 18–75 - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+ - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT05664113RecruitingPhase 1
Fecal transplant for gut problems after stem cell transplant
This study tests whether transplanting healthy donor stool into the gut can help children and young adults with ongoing digestive issues after a stem cell transplant. It may improve symptoms like diarrhea or the need for feeding tubes.
Memphis, TennesseeAges Up to 22 years
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,736 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.